688276.SH
Changchun BCHT Biotechnology Co.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 16.23
+1.31%Sep 22, 2026, 10:52 UTC
China's National Medical Products Administration accepted Baike Biotech's clinical trial application (acceptance number CXSL2601038) for a recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination product intended to prevent lower respiratory tract infections caused by RSV in newborns and infants.
Aug 20, 2026, 11:30 UTC
Baike Biological announced its 2026 first-half results: net loss attributable to shareholders narrowed to 52.1001 million yuan from 73.5734 million yuan a year earlier, with revenue up 6.89% to 305 million yuan.
Source: